BioSpace News Archive

Marking a milestone in pharmaceutical innovation and excellence, Dr. Ferrer BioPharma has been honored with a prestigious award at the renowned CPHI Pharmapack 2024, which took place at the Paris Expo, Porte de Versailles.

The Scleroderma Research Foundation announces the appointment of Gregory Gordon, MD, JD as its first Chief Medical Officer.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biological products, congratulates the Company’s co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.

Vera Therapeutics, Inc. today announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.

Panbela Therapeutics, Inc. announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer.

FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG , a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions.

Soligenix, Inc. today that the Company will deliver a corporate presentation at The Microcap Conference.

Organovo Holdings, Inc. (Nasdaq: ONVO) today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the Crohn’s and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada.

Eli Lilly and Company announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.